TOP10 ammunition equipment for pharmaceutical companies in the first half of 2021

Wen | Muyi

To expand territory, ammunition goes first

The Chinese market has always been a battleground for military strategists.

Note: The data comes from the Insight database reporting progress module, not based on the parent company's statistics

Leading pharmaceutical companies in innovative drugs have obvious advantages

Hengrui Medicine ranked first and performed well

At the same time, it is worth mentioning that in the first half of 2021, 12 products of Hengrui are all new projects approved for clinical entry for the first time

Foreign companies have a strong presence in the approved clinical list.

The veteran giant AstraZeneca ranked third, with 14 drugs approved for clinical use, and 10 anti-tumor drugs focused on deployment

CP Tianqing surpassed Merck and Novartis to rank fourth, making the number of approved pharmaceutical companies more than 10 accounted for half of the country

Domestic pharmaceutical companies accelerate the development of innovative drugs

Among the top ten approved pharmaceutical companies, there are 11 multinational pharmaceutical companies and 7 domestic pharmaceutical companies, almost equally divided.

BeiGene focuses on new anti-tumor drugs, and currently all six clinical trials have reached this point

TOP20 domestic pharmaceutical companies with R&D investment in 2020 (Unit: RMB 100 million)

From: Corporate Annual Report, Insight database compilation

Biological drugs came from behind, but popular targets are still congested

At present, from the perspective of drug types, although chemical drugs and biological products are divided into two parts, chemical drugs still dominate.

However, from the perspective of target combing, the crowding phenomenon is still serious.

In the field of treatment, the involved areas correspond to the several diseases with the highest incidence

summary

Based on the 2018-2021 domestic and foreign pharmaceutical companies' CDE approved clinical project trends, the approval of domestic new drugs continues to advance by leaps and bounds, and domestic innovative drugs have initially completed the initial accumulation of early stage.